> Nymox Pharmaceutical announced positive results from its newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia. Company officials say the trial demonstrated statistically significant results. Release
> Canada's Miraculins announced that an ongoing biomarker study demonstrated that its biomarker diagnostic would have eliminated the need for 20 percent of the biopsies for patients without prostate cancer while demonstrating 96 percent effectiveness in identifying true positives. Release
> Pfizer India has sold a manufacturing facility to CSJ Infastructure for $63 million. Report
And Finally... Researchers at Cardiff University say that genetics plays a key role in heavy substance abuse. Report